Olathe, Kansas; General Obligation Apr 08

  • ID: 1721271
  • April 2008
  • Region: Kansas
  • Standard & Poors
1 of 3

Standard & Poor's Ratings Services raised its standard long-term rating and underlying rating (SPUR) on Olathe, Kan.'s general obligation (GO) bonds to 'AA+' from 'AA'. The outlook is stable. The upgrade reflects the city's continued tax base growth and diversification, coupled with the maintenance of very strong general fund balance reserves. The rating action affects roughly $170 million of GO debt. In addition, Standard & Poor's assigned its 'AA+' rating, and stable outlook, to the city's series 211 GO bonds. The ratings reflect the city's: Participation in the strong Kansas City MSA, Economic diversification through ongoing commercial and industrial development, Very strong wealth and income levels, Establishment of policies and procedures to ensure it will address continued growth in a...

Companies mentioned in this report are:
- Olathe

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3


Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.